Core Facilities Essen/Düsseldorf
© iStock.com /zmeel photography
BioChip Laboratory, University Hospital Essen
The BioChip Laboratory conducts Affymetrix microarray analysis and "Next Generation Sequencing" for the Departments of the local Faculty of Medicine, the University of Duisburg-Essen and various collaborative basic research projects as well as clinical trials.
Imaging Facility IMCES, University Hospital Essen
IMCES is a core facility within the Institut für Experimentelle Immunologie und Bildgebung at the Faculty of Medicine, Universitätsklinikum Essen and Universität Duisburg-Essen. The facility brings together state-of-the-art equipment and expertise in light and electron microscopy, in vivo and intravital imaging, and image analysis. These services are available to all researchers, irrespective of location and affiliation.
The IMCES laboratories and microscopy rooms have permission for working at the S1 and S2 biological safety level.
WTZ Precision Oncology Program (WTZ-POP) and WTZ Immune Oncology Program (WTZ-IOP)
Since 2012 all patients with advanced cancers presenting to the West German Cancer Center (WTZ) of University Hospital Essen, one of 13 German Oncology Centers of Excellence designated by the German Cancer Aid, are offered participation in WTZ-POP and WTZ-IOP. The program was developed based on a pilot study in breast cancer patients starting in 2010 (Welt A et al. Breast Cancer Treat 2013). Patients eligible for systemic cancer therapy and study treatment are offered "preemptive" analysis of a broad biomarker panel including NGS-based panel sequencing, immunohistochemistry, in situ hybridization and others (Wiesweg et al. Eur J Cancer 2013). All biomarkers are selected based on their relation to clinically approved medicines or active precision oncology and immunooncology studies. Biomarker findings are linked with clinical data and treatment information and are following longitudinally in the WTZ Tumor Documentation System. Each year approximately 500 patients are studied within WTZ-POP and WTZ-IOP, and the data base already comprises more than 2,000 patients. Focus entities include lung cancer, melanoma, gastrointestinal cancers including pancreatic and biliary tract cancers, sarcoma and GIST, and breast cancer. By these programs patients with advanced cancers are effectively offered access to precision therapies particularly within clinical trials (Flaherty et al., N Engl J Med 2012, Sequist et al., J Clin Oncol 2013, Shaw et al. N Engl J Med 2014, Robert et al., N Engl J Med 2015, Brahmer et al. N Engl J Med 2015, Hyman et al. N Engl J Med 2015, Larkin et al. N Engl J Med 2015). In addition, this prospective and unbiased program including comprehensive documentation of clinical findings enables clinical characterization and validation of prognostic and predictive biomarkers, and studies of patient benefits of precision oncology and immunooncology (Zimmer et al., J Clin Oncol 2012, Schadendorf et al, J Clin Oncol 2015, Reis et al. Lung Cancer 2015, Wiesweg et al. J Thorac Oncol 2016).